284 related articles for article (PubMed ID: 28804110)
21. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
22. FDG PET imaging in patients with pathologically verified dementia.
Hoffman JM; Welsh-Bohmer KA; Hanson M; Crain B; Hulette C; Earl N; Coleman RE
J Nucl Med; 2000 Nov; 41(11):1920-8. PubMed ID: 11079505
[TBL] [Abstract][Full Text] [Related]
23. The Use of
Ortner MM
Methods Mol Biol; 2018; 1750():213-219. PubMed ID: 29512075
[TBL] [Abstract][Full Text] [Related]
24. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
Foster NL; Heidebrink JL; Clark CM; Jagust WJ; Arnold SE; Barbas NR; DeCarli CS; Turner RS; Koeppe RA; Higdon R; Minoshima S
Brain; 2007 Oct; 130(Pt 10):2616-35. PubMed ID: 17704526
[TBL] [Abstract][Full Text] [Related]
25. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
[TBL] [Abstract][Full Text] [Related]
26. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review.
Davison CM; O'Brien JT
Int J Geriatr Psychiatry; 2014 Jun; 29(6):551-61. PubMed ID: 24123413
[TBL] [Abstract][Full Text] [Related]
27. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Garibotto V; Herholz K; Boccardi M; Picco A; Varrone A; Nordberg A; Nobili F; Ratib O;
Neurobiol Aging; 2017 Apr; 52():183-195. PubMed ID: 28317648
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography diagnosis of Alzheimer's disease.
Coleman RE
Neuroimaging Clin N Am; 2005 Nov; 15(4):837-46, x. PubMed ID: 16443494
[TBL] [Abstract][Full Text] [Related]
29. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer's disease.
Scheltens P; Blennow K; Breteler MM; de Strooper B; Frisoni GB; Salloway S; Van der Flier WM
Lancet; 2016 Jul; 388(10043):505-17. PubMed ID: 26921134
[TBL] [Abstract][Full Text] [Related]
31. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies.
Dukart J; Mueller K; Horstmann A; Vogt B; Frisch S; Barthel H; Becker G; Möller HE; Villringer A; Sabri O; Schroeter ML
Neuroimage; 2010 Jan; 49(2):1490-5. PubMed ID: 19770055
[TBL] [Abstract][Full Text] [Related]
33. PET radiotracers for molecular imaging in dementia.
Baskin A; Giannakopoulos P; Ratib O; Seimbille Y; Assal F; Perani D; Garibotto V
Curr Radiopharm; 2013 Dec; 6(4):215-30. PubMed ID: 24283962
[TBL] [Abstract][Full Text] [Related]
34. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
35. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.
Silverman DH
J Nucl Med; 2004 Apr; 45(4):594-607. PubMed ID: 15073255
[TBL] [Abstract][Full Text] [Related]
36. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
[TBL] [Abstract][Full Text] [Related]
38. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP.
Kono AK; Ishii K; Sofue K; Miyamoto N; Sakamoto S; Mori E
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1490-7. PubMed ID: 17318545
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid tau protein levels and 18F-fluorodeoxyglucose positron emission tomography in the differential diagnosis of Alzheimer's disease.
Yakushev I; Bartenstein P; Siessmeier T; Hiemke C; Scheurich A; Lotz J; Fellgiebel A; Müller MJ
Dement Geriatr Cogn Disord; 2010; 30(3):245-53. PubMed ID: 20847555
[TBL] [Abstract][Full Text] [Related]
40. New approaches in nuclear medicine for early diagnosis of Alzheimer's disease.
Mirzaei S; Gelpi E; Booij J; Rodrigues M; Neumann I; Zaknun J; Koehn H; Knoll P
Curr Alzheimer Res; 2004 Aug; 1(3):219-29. PubMed ID: 15975069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
